News
published at: 29.04.2026
MDS Therapy: Dresden Team Demonstrates Tasquinimod’s Potential for Improved Blood Formation and Treatment of Bone Damage
Researchers at Dresden University Hospital may have discovered a new therapeutic approach for treating myelodysplastic syndromes (MDS). In a recent study, the team headed by Prof. Manja Wobus and Dr. Katja Sockel demonstrated that the anti-inflammatory drug tasquinimod improves blood formation—which is impaired in MDS—and reduces bone damage in preclinical models. Their findings address two central and closely related clinical issues associated with MDS. The corresponding study on the preclinical efficacy of tasquinimod in myelodysplastic syndromes was recently published in the journal “HemaSphere,” a specialist journal for hematology.
